SOTIO

Innovative, clinical-stage biopharmaceutical company developing targeted cancer therapies with first-in-class and best-in-class potential. Member of @PPFGroup.

[SOTIO @SOTIO]

November is both Pancreatic Cancer Awareness Month and Stomach Cancer Awareness Month – two cancer types greatly in need of new treatment options. We’re advancing a clinical trial of #ADC SOT109 as a potential therapeutic option for gastrointestinal cancers. SOT109 targets CDH17, a protein abundantly expressed in GI cancers, including CRC, stomach, pancreatic, and esophageal cancers.

We remain committed to advancing innovative therapies with the potential to make a difference for patients.
#PancreaticCancerAwareness #StomachCancerAwareness #Oncology #Cancer

[SOTIO @SOTIO]

Our Chief Scientific Officer Amy Jensen-Smith has been recognized by @HealthTechRPT as one of this year’s Top Women Leaders in Biotech and Life Sciences! Since joining SOTIO more than five years ago, Amy has played an instrumental role in advancing our scientific vision and pipeline. From leading global discovery and preclinical research to helping guide our next-generation #ADCs toward clinical development, her scientific leadership continues to shape what’s ahead for SOTIO. Congratulations, Amy, on this well-deserved recognition!

See the report: https://t.co/ONOyuL7jGd

[SOTIO @SOTIO]

We’re on the ground at #SITC26 and looking forward to presenting the first clinical data on SOT201, our PD-1 targeting IL-15 immunocytokine. Interim data from the Phase 1 VICTORIA-01 clinical trial show early evidence of durable antitumor activity with SOT201, including responses in patients whose #cancer had progressed after checkpoint inhibitor therapy.

Read more in today’s press release: https://t.co/fChXsTaCZo

@sitcancer
#CancerImmunotherapy #Immunocytokine #DrugDevelopment #ClinicalTrials

[SOTIO @SOTIO]

This month we are heading to @EBDgroup’s #BIOEurope2026 in Germany to connect with potential collaborators and explore opportunities to advance our oncology pipeline.

With two next-generation ADC programs in development for solid tumors, we’re interested in conversations around partnering, licensing, and investment with companies and investors focused on bringing differentiated cancer therapies to patients.

If you would like to arrange a meeting with our BD team, please reach out to [email protected].
#BiotechPartnering #ADC #Oncology

[SOTIO @SOTIO]

Next week at #SITC2026 we will present initial data from VICTORIA-01, our Phase 1 study evaluating SOT201 in patients with advanced or metastatic solid tumors. SOT201 is a novel cis-acting immunocytokine, combining IL-15 superagonist and anti-PD-1 activity in order to stimulate tumor specific T cells. We’re looking forward to engaging with the #CancerImmunotherapy community and sharing these promising data.
@sitcancer #Immunotherapy

[SOTIO @SOTIO]

Cadherin-17, or #CDH17, is a clinically-validated target highly prevalent across gastrointestinal cancers, with expression in the vast majority of colorectal cancer (#CRC) primary tumors and metastases, as well as a substantial proportion of primary gastric tumors. With limited expression outside the GI tract, CDH17 represents an attractive target for precision therapies like antibody-drug conjugates (#ADCs).

CDH17 is the target of SOT109, our next-generation #ADC designed for GI cancers, which recently entered the clinic in the Phase 1/2 CADENCIA-01 clinical trial.

We’re pleased to be recognized by @PharmaVoice as a frontrunner in the CDH17 space. Read more about the emerging drug targets pharma is betting on next: https://t.co/POtHl1Z1Xt

#Oncology #DrugDevelopment #ColorectalCancerInnovation

[SOTIO @SOTIO]

Our CSO Amy Jensen-Smith, Ph.D., sat down with the @medicine_maker to discuss her path from bench to scientific leadership, and what it takes to build teams where curiosity, experimentation and learning are part of the process.

Amy has worked in academia, at @theNCI, in big pharma and now in biotech. Along the way, she’s seen the value of academic freedom, the importance of staying close to patients, and why biotech can offer the resources and focus needed to move new ideas forward.

That thinking shapes how we approach drug development at SOTIO. Rather than working through every question in order, we look for the question that could stop a program and test it first. By tackling the biggest risks early, we can see what’s worth pursuing and what isn’t.

Read the full conversation below.

#ADC #Oncology #DrugDevelopment #WomenInScience

[The Medicine Maker @medicine_maker]

What if the smartest move in drug development is knowing when to walk away?

SOTIO Biotech's Amy Jensen-Smith explains why testing a drug program's biggest weakness first could save time and resources.

🔗 https://t.co/TXcEecF6e7

#DrugDiscovery #Biotech

[SOTIO @SOTIO]

Our CADENCIA-01 Phase 1/2 clinical trial evaluating our potentially best-in-class #ADC SOT109 has been featured among the “five new colorectal cancer clinical trials you should know about” in @cure_today.

Dosing the first patient last month marked an important step as we advance SOT109 into the clinic and begin generating initial clinical data. As the only CDH17-targeting ADC that has been granted U.S. @FDA Fast Track Designation, SOT109 is uniquely positioned within the emerging CDH17 landscape and has the potential to become a differentiated treatment option for patients with advanced gastrointestinal cancers.

Read the full article: https://t.co/xwBRrOwCs1
#Oncology #DrugDevelopment

[SOTIO @SOTIO]

We’re heading to #ESMO26! As we continue to advance our portfolio of clinical-stage #ADCs for difficult-to-treat solid tumors, we look forward to discussing emerging oncology trends and exploring opportunities for collaboration with potential partners at the @myESMO Congress.

Please reach out to [email protected] if you’re interested in connecting.
#ESMO26 #ADC #Oncology #Biotech #DrugDevelopment #Partnering

[SOTIO @SOTIO]

At @World_ADC San Diego, Martin Vodak looks forward to connecting with companies and investors to discuss the future of antibody-drug conjugates (#ADCs) for the treatment of solid tumors.

With two ADC programs entering the clinic in 2026, we’re advancing targeted therapies designed to address significant unmet needs in #CRC and #sarcoma, with the potential to deliver new treatment options for patients.
#WorldADC #WorldADCSanDiego #DrugDevelopment #OncologyInnovation

[SOTIO @SOTIO]

Next month, the Life Science Legal Strategy Summit, organized by @KisacoRes, brings together legal, IP, and life sciences professionals from across the industry. SOTIO's Christoph Rehfuess will join fellow experts for a panel discussion on strategies for protecting antibody innovation across Europe and the U.S. As the legal landscape for biologics continues to evolve, the session will explore key considerations for securing robust IP portfolios.
#LSLS2026 #LifeSciences #PatentStrategy #DrugDevelopment

[SOTIO @SOTIO]

Today is World Cancer Research Day, recognizing the discoveries driving progress in #cancer care. Across SOTIO’s ADC platform, one focus of our research has been expanding the therapeutic window of these therapies.

The therapeutic window is the dose range of a medicine that provides effective therapy and avoids serious side effects. A wider therapeutic window means more flexibility in dosing and a larger safety margin.

Our research aims to expand our ADC candidates’ therapeutic windows by innovating in target identification, linker technology, and antibody design – with the end goal of creating safe and effective therapies for cancer types with very few treatment options today.

Learn more about our ADC research: https://t.co/mHVga7KzD6

#WorldCancerResearchDay #CancerResearch #Oncology #ADC

[SOTIO @SOTIO]

SOT106 has received two additional designations from @FDA: Orphan Drug Designation for #SoftTissueSarcoma and Fast Track Designation for #Osteosarcoma.
Our potentially best-in-class investigational ADC targeting LRRC15 now holds both designations for both primary types of sarcoma. With a first-in-human clinical trial expected to begin later this year, SOTIO is advancing development of SOT106 with the hope of delivering a targeted therapy with benefit across sarcoma subtypes. Read more in today’s press release: https://t.co/NUTEi6LjNN

#FastTrackDesignation #OrphanDrugDesignation #ADC #Sarcoma

[SOTIO @SOTIO]

Next week, we will be at the ADC Symposium here in our home city of Prague. Zuzana Antošová, Director, Bioanalysis & Pharmacokinetics, will deliver an oral presentation exploring how ADC stability and species-specific biology influence pharmacokinetics, safety, and the translation of preclinical findings into human PK prediction. We look forward to joining colleagues in conversations at the cutting edge of ADC drug development!
#ADC #DrugDevelopment

[SOTIO @SOTIO]

Today we announced that the first patient has been dosed in our Phase 1/2 CADENCIA-01 study evaluating SOT109, a next-generation antibody-drug conjugate (#ADC) targeting cadherin-17 (CDH17) for the treatment of colorectal cancer. This milestone reflects our continued commitment to advancing innovative therapies with the potential to expand treatment options and improve outcomes for people living with CRC and other GI cancers. Read more in today’s press release: https://t.co/LlYSeJhMHZ
#FirstPatientDosed #FPD #TrialInitation #ColorectalCancerInnovation #DrugDevelopment #ClinicalTrials

[SOTIO @SOTIO]

Thank you for your visit and the insightful discussion, @USEmbassyPrague!

[U.S. Embassy Prague 🇺🇸🇨🇿 @USEmbassyPrague]

„Nadějná léčba proti rakovině se vyvíjí jak v Praze, tak v Bostonu. 🚀 Skvělá návštěva pražské centrály společnosti @SOTIO! 🇨🇿🇺🇸 Tato česká společnost s pobočkou v Bostonu spojuje špičkový výzkum, inovace v biotechnologii a onkologii. Děkuji za inspirativní diskusi!“ 🧬🔬💊 #AmbMerrick

[SOTIO @SOTIO]

The U.S. Food and Drug Administration (@FDA ) has accepted our investigational new drug (IND) application for SOT106, enabling a first-in-human Phase 1/2 trial in patients with #osteosarcoma and soft tissue sarcoma. SOT106 is an investigational antibody-drug conjugate (#ADC) targeting LRRC15, a clinically validated target broadly expressed across multiple highly prevalent #sarcoma subtypes. Sarcomas are a diverse group of cancers with limited targeted treatment options, and this milestone moves a potential best-in-class therapy one step closer to patients with sarcoma and other LRRC15-positive malignancies. We look forward to sharing additional updates as SOT106 advances into clinical development.
#INDAcceptance #DrugDevelopment #ClinicalTrials #OncologyResearch

[SOTIO @SOTIO]

The U.S. Food and Drug Administration (@FDA ) has granted Fast Track Designation to SOT106, our potentially best-in-class investigational antibody-drug conjugate targeting leucine-rich repeat-containing 15 (#LRRC15), for the treatment of #SoftTissueSarcoma. This designation underscores the significant unmet need for soft tissue sarcoma and the potential of SOT106 to bring a targeted #ADC approach to patients with few options today. It follows the Orphan Drug Designation granted to SOT106 for osteosarcoma in May, further supporting its development across sarcoma. Read more in today's press release: https://t.co/hSseTG80Uy
#FastTrackDesignation #FTD #Sarcoma #DrugDevelopment

[SOTIO @SOTIO]

Proud to see our Chief Scientific Officer, Amy Jensen-Smith, featured in @bizwomenreports' "In Her Own Words" series. In the essay, Amy reflects on the pivotal moment that set her on the path to cancer drug development, reflects on her journey from bench scientist to Chief Scientific Officer, and explains why the greatest challenges within the solid tumor treatment paradigm remain her biggest motivation. From helping bring CAR-T therapies from early breakthroughs to approved treatments, Amy now leads the advancement of our ADC pipeline, advancing a portfolio of antibody-drug conjugates for the treatment of various solid tumors. Her scientific leadership shapes how we pursue better options for the patients who need them most. Read her story: https://t.co/WvGfiKWJGz
#Oncology #CancerResearch #WomenInScience #Biotech #DrugDevelopment #ADC